【摘要】：目的:系統(tǒng)評價復方苦參注射液聯(lián)合含奧沙利鉑化療方案治療大腸癌的療效和安全性,為臨床提供循證參考。方法:計算機檢索相關期刊論文、萬方數(shù)據(jù)庫、中國生物醫(yī)學文獻數(shù)據(jù)庫、中文科技期刊數(shù)據(jù)庫、PubMed、Cochrane圖書館,收集復方苦參注射液聯(lián)合含奧沙利鉑化療方案(試驗組)對比常規(guī)化療方案(對照組)治療大腸癌的隨機對照試驗(RCT),提取資料并依據(jù)改良的Jadad量表進行質(zhì)量評價后,采用RevMan 5.3統(tǒng)計軟件進行Meta分析。結果:最終納入33項RCT,合計2 801例患者。Meta分析結果顯示,試驗組患者近期有效率[RR=1.34,95%CI(1.24,1.46),P0.001]、功能狀態(tài)(KPS)評分改善率[RR=1.87,95%CI(1.65,2.14),P0.001]、CD4~+/CD8~+[WMD=0.49,95%CI(0.26,0.72),P0.001]、CD4~+水平[WMD=10.34,95%CI(7.00,13.69),P0.001]、CD3~+水平[WMD=5.85,95%CI(4.07,7.62),P0.001]、自然殺傷細胞水平[WMD=3.52,95%CI(1.76,5.27),P0.001]、白細胞介素(IL)-2水平[WMD=12.96,95%CI(10.39,15.53),P0.001]顯著高于對照組,CD8~+水平[WMD=-5.89,95%CI(-11.39,-0.40),P=0.04]、IL-10水平[WMD=-21.04,95%CI(-29.15,-12.94),P0.001]、惡心嘔吐發(fā)生率[RR=0.72,95%CI(0.67,0.78),P0.001]、白細胞減少發(fā)生率[RR=0.52,95%CI(0.45,0.61),P0.001]、肝功能異常發(fā)生率[RR=0.63,95%CI(0.53,0.74),P0.001]、周圍神經(jīng)毒性發(fā)生率[RR=0.77,95%CI(0.64,0.92),P=0.005]顯著低于對照組,差異均有統(tǒng)計學意義。結論:復方苦參注射液聯(lián)合含奧沙利鉑化療方案治療大腸癌療效優(yōu)于單純化療,可以提高患者生存質(zhì)量,改善免疫功能,降低化療引起的不良反應。
[Abstract]:Objective: to evaluate the efficacy and safety of compound Sophora flavescens injection combined with oxaliplatin chemotherapy in the treatment of colorectal cancer. Methods: the full text database of Chinese periodicals, Wanfang database, Chinese biomedical literature database, Chinese sci-tech journal database, PubMed,Cochrane library were searched by computer. To collect the data of (RCT), extraction from the randomized controlled trial of compound Sophora flavescens injection combined with oxaliplatin chemotherapy regimen (trial group) and compare with conventional chemotherapy regimen (control group) and evaluate the quality according to the modified Jadad scale. Meta analysis was carried out with RevMan 5.3 statistical software. Results: 33 items of RCT, were included in the total of 2 801 patients. The results of Meta analysis showed that the short-term effective rate of patients in the trial group [RR=1.34,95%CI (1.24 鹵1.46), P0.001]. The improvement rate of (KPS) score of functional state [RR=1.87,95%CI (1.65m2.14), P0.001], CD4~ / CD8~ [WMD=0.49,95%CI (0.260.72), P0.001], CD4~ level [WMD=10.34,95%CI (7.000.69), P0.001]; The levels of CD3~ [WMD=5.85,95%CI (4.07, 7.62), P0.001], natural killer cells [WMD=3.52,95%CI (1.76m5.27), P0.001], interleukin (IL) 2 (WMD=12.96,95%CI (10.39) 15.53), The levels of CD8~ [WMD=-5.89,95%CI (-11.39) -0.40], P0. 04, IL-10 [WMD=-21.04,95%CI (-29.15-12.94), P0. 001] were significantly higher than those in the control group. The incidence of nausea and vomiting [RR=0.72,95%CI (0.67 ~ 0.78), P0.001], leukopenia [RR=0.52,95%CI (0.450.61), P0.001], the incidence of abnormal liver function [RR=0.63,95%CI (0.53 鹵0.74)], The incidence of peripheral neurotoxicity [RR=0.77,95%CI (0.64 鹵0.92), P _ (0.005)] was significantly lower than that of the control group (P 0.001), and the difference was statistically significant. Conclusion: the therapeutic effect of compound Sophora flavescens injection combined with oxaliplatin chemotherapy in the treatment of colorectal cancer is better than that of chemotherapy alone, which can improve the quality of life, improve the immune function and reduce the adverse reactions caused by chemotherapy.
【作者單位】： 廣州中醫(yī)藥大學第四臨床醫(yī)學院/深圳市中醫(yī)院;廣州中醫(yī)藥大學第二臨床醫(yī)學院;
【分類號】：R735.34

【相似文獻】

相關期刊論文 前10條

1 蔣建龍;;復方苦參注射液治療惡性腫瘤的療效觀察[J];山東醫(yī)藥;2009年24期

2 ;振東杯巖舒~汶復方苦參注射液有獎征文通知[J];山西中醫(yī);2009年08期

3 蘇全勝;薛利軍;林勇;楊繼紅;于正洪;林R，

本文編號：2319619